Sexual Health

Data suggest that thermal biomodulation via radiofrequency improves vaginal lubrication and reduces pain during intercourse for postmenopausal women.

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 lb.

Phase 3 results show oral zoliflodacin was non-inferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

DARE to PLAY sildenafil cream is now available for prescribing in select states as a non-hormonal topical option to improve genital blood flow and arousal.

A US study of women over 60 found that frequent sex toy use during masturbation was strongly associated with higher orgasm frequency.

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in a Q&A.

Innovations in diagnostic testing enhance patient care, empowering women with at-home options and faster access to essential health services.

Experts discuss the FDA's priority review of gepotidacin, an oral gonorrhea treatment, highlighting its potential to improve women's health and access to care.

Experts discuss updates in STI testing, congenital conditions, and best practices for pregnant women in this insightful healthcare panel.

Universal EHR-based decision support eliminated racial disparities in adolescent chlamydia and gonorrhea testing in pediatric EDs.

Study finds women 65+ experience sexual dysfunction at rates similar to midlife women but report less distress over sexual health concerns.

FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients 12 years and older.

The FDA has granted priority review to expand flibanserin (Addyi; Sprout Pharmaceuticals) use to postmenopausal women, potentially broadening access to treatment for hypoactive sexual desire disorder.

The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

New research highlights the link between postpartum posttraumatic stress disorder and sexual dysfunction, emphasizing the need for early screening and trauma-informed care.

Sexual inactivity worsens SSRI side effects in women, but gepirone-ER shows fewer impacts.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Somi Javaid, MD, FACOG, urges clinicians to prioritize sexual health care through specialized training or referrals, highlighting the importance of patient empowerment and emerging treatments such as testosterone therapy and pelvic floor health tools.

Discover how a comprehensive biopsychosocial approach addressing biological, psychological, and social factors can improve sexual health, boost confidence, and enhance overall well-being.

Despite sexual health being a fundamental right, women face significant disparities in treatment, awareness, and insurance coverage—highlighting the need for systemic change.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.